Health Decisions Encourages DIA Attendees to Demand More Than the Industry’s 10% Rate of On-Time Enrollment in Clinical Trials (Booth 929)
CRO demonstrates techniques that reverse the tide of enrollment delays in clinical research.
Durham, NC, May 29, 2010 --(PR.com)-- Full-service contract research organization (CRO) Health Decisions (www.HealthDec.com) will launch the “Demand More” campaign at the 46th DIA Annual Meeting, June 13 – 17 in Washington, D.C. (Booth #929). Attendees will be able to experience demonstrations of trial management techniques that meet or exceed enrollment goals for 83 percent of studies.
Clinical studies conducted at U.S. investigative sites met patient enrollment deadlines only 10 percent of the time in 2009, according to an industry survey, and were delayed by more than a month 68 percent of the time. Recent surveys conducted in Latin America, Asia Pacific, Europe, and Canada paint a picture almost as bleak, with studies enrolling on time at a rate of only 14 – 17 percent.
“A success rate of only 10 percent is unacceptable for meeting enrollment goals on time,” said Rick Farris, chief operating officer at Health Decisions. “We will show DIA attendees a practical solution to enrollment delays that is available now. There is no need for sponsors to settle for the poor enrollment performance documented in industry surveys.”
“Enrollment issues are costing sponsors countless days of development time, each of which amounts to more than a million dollars in lost sales according to industry estimates,” said Farris. “A methodology that we call Agile Clinical Development enrolls studies on time and prevents these huge losses. Industry executives would never do business with a shipping company that delivers only 10 percent of their packages on time or distributes only 10 percent of their products on time. They shouldn’t accept a CRO that meets clinical trial enrollment deadlines only 10 percent of the time either.”
According to Farris, the crux of Agile Clinical Development is informed flexibility. It’s designed to grant researchers the power to adapt a study’s operations—including enrollment strategy and tactics—based on meaningful, continuously updated investigative site performance metrics. Farris says the industry can and should expect improved success rates not only in enrollment, but for entire clinical programs and R&D pipelines.
“The Agile methodology makes it easy to see what’s working, what isn’t, and—most importantly—why,” said Farris. “Immediate access to this type of information makes it easy to optimize for successful enrollment strategies and techniques, and to prevent the waste of resources on nonproductive activities. It also quickly alerts study managers when more drastic remedies are required, such as adjusting enrollment criteria or expanding into other geographic regions.”
Health Decisions invites DIA Annual Meeting attendees to visit booth #929 to see for themselves how Agile Clinical Development can improve enrollment speed and success. The “Demand More” exhibit will demonstrate part of the system that makes this possible, engaging attendees to experience the constant, seamless flow of information from investigative sites to sponsor reports.
According to Farris, the benefits of Agile Clinical Development extend not just to enrollment, but to every aspect of study operations. “Meeting or exceeding the enrollment deadline sets the baseline of success for the overall study,” he said. “But Agile Clinical Development tools and processes also produce substantial efficiency gains in data management, site monitoring, site closeout, and database lock. Sponsors get better results because they are better informed and exercise greater control over their own studies.”
For more information, please contact Katie Hendrick, Marketing Specialist; khendrick@HealthDec.com; +1.919.967.1111 x116
For sales and marketing information, or to schedule a meeting, please contact Dean Bundschu, VP of Business Development; dbundschu@HealthDec.com; +1.919.967.1111 x510
About Health Decisions
Health Decisions (www.HealthDec.com) is a global clinical research organization (CRO) committed to helping drug and device companies achieve greater success. Our sponsors rely on us to help them prove the value of their pipelines both faster and with the smartest possible allocation of funds. Through Agile Clinical Development—a strategic combination of adaptive design and adaptive operations—Health Decisions optimizes every facet of clinical research from design protocol to the most detailed day-to-day management, so sponsors can make the most of competitive market opportunities.
Health Decisions has over twenty years of experience helping sponsors achieve success in Phase I-IV trials across all major therapy areas. For more information, please visit the company's website at (www.HealthDec.com).
About the DIA Annual Meeting
Hosted by the Drug Information Association, the DIA 46th Annual Meeting takes place June 13 – 17, 2010 at the Walter E. Washington Convention Center, Washington, DC. The DIA Annual Meeting is the biopharmaceutical industry's largest, longest running, best-value, global, multidisciplinary event. To learn more, visit DIA online at www.diahome.org.
###
Clinical studies conducted at U.S. investigative sites met patient enrollment deadlines only 10 percent of the time in 2009, according to an industry survey, and were delayed by more than a month 68 percent of the time. Recent surveys conducted in Latin America, Asia Pacific, Europe, and Canada paint a picture almost as bleak, with studies enrolling on time at a rate of only 14 – 17 percent.
“A success rate of only 10 percent is unacceptable for meeting enrollment goals on time,” said Rick Farris, chief operating officer at Health Decisions. “We will show DIA attendees a practical solution to enrollment delays that is available now. There is no need for sponsors to settle for the poor enrollment performance documented in industry surveys.”
“Enrollment issues are costing sponsors countless days of development time, each of which amounts to more than a million dollars in lost sales according to industry estimates,” said Farris. “A methodology that we call Agile Clinical Development enrolls studies on time and prevents these huge losses. Industry executives would never do business with a shipping company that delivers only 10 percent of their packages on time or distributes only 10 percent of their products on time. They shouldn’t accept a CRO that meets clinical trial enrollment deadlines only 10 percent of the time either.”
According to Farris, the crux of Agile Clinical Development is informed flexibility. It’s designed to grant researchers the power to adapt a study’s operations—including enrollment strategy and tactics—based on meaningful, continuously updated investigative site performance metrics. Farris says the industry can and should expect improved success rates not only in enrollment, but for entire clinical programs and R&D pipelines.
“The Agile methodology makes it easy to see what’s working, what isn’t, and—most importantly—why,” said Farris. “Immediate access to this type of information makes it easy to optimize for successful enrollment strategies and techniques, and to prevent the waste of resources on nonproductive activities. It also quickly alerts study managers when more drastic remedies are required, such as adjusting enrollment criteria or expanding into other geographic regions.”
Health Decisions invites DIA Annual Meeting attendees to visit booth #929 to see for themselves how Agile Clinical Development can improve enrollment speed and success. The “Demand More” exhibit will demonstrate part of the system that makes this possible, engaging attendees to experience the constant, seamless flow of information from investigative sites to sponsor reports.
According to Farris, the benefits of Agile Clinical Development extend not just to enrollment, but to every aspect of study operations. “Meeting or exceeding the enrollment deadline sets the baseline of success for the overall study,” he said. “But Agile Clinical Development tools and processes also produce substantial efficiency gains in data management, site monitoring, site closeout, and database lock. Sponsors get better results because they are better informed and exercise greater control over their own studies.”
For more information, please contact Katie Hendrick, Marketing Specialist; khendrick@HealthDec.com; +1.919.967.1111 x116
For sales and marketing information, or to schedule a meeting, please contact Dean Bundschu, VP of Business Development; dbundschu@HealthDec.com; +1.919.967.1111 x510
About Health Decisions
Health Decisions (www.HealthDec.com) is a global clinical research organization (CRO) committed to helping drug and device companies achieve greater success. Our sponsors rely on us to help them prove the value of their pipelines both faster and with the smartest possible allocation of funds. Through Agile Clinical Development—a strategic combination of adaptive design and adaptive operations—Health Decisions optimizes every facet of clinical research from design protocol to the most detailed day-to-day management, so sponsors can make the most of competitive market opportunities.
Health Decisions has over twenty years of experience helping sponsors achieve success in Phase I-IV trials across all major therapy areas. For more information, please visit the company's website at (www.HealthDec.com).
About the DIA Annual Meeting
Hosted by the Drug Information Association, the DIA 46th Annual Meeting takes place June 13 – 17, 2010 at the Walter E. Washington Convention Center, Washington, DC. The DIA Annual Meeting is the biopharmaceutical industry's largest, longest running, best-value, global, multidisciplinary event. To learn more, visit DIA online at www.diahome.org.
###
Contact
Health Decisions
Kate Hendrick, Marketing Specialist
919-960-1111x116
www.HealthDec.com
2510 Meridian Parkway
Durham, NC 27713
Kate Hendrick, Marketing Specialist
919-960-1111x116
www.HealthDec.com
2510 Meridian Parkway
Durham, NC 27713
Contact
Categories